Subtopic Deep Dive
Secondary Prevention after Ischemic Stroke
Research Guide
What is Secondary Prevention after Ischemic Stroke?
Secondary prevention after ischemic stroke uses antiplatelet therapy, statins, anticoagulants, and lifestyle modifications to reduce recurrent stroke risk in survivors.
Meta-analyses like Zhang et al. (2014) with 11,545 citations evaluate aspirin plus clopidogrel efficacy for non-cardioembolic stroke prevention. Guidelines from Kernan et al. (2014, 5,153 citations) and Jauch et al. (2013, 7,614 citations) provide evidence-based recommendations on antiplatelet regimens and risk factor management. Over 20 guidelines and trials shape current protocols.
Why It Matters
Antiplatelet regimens halve recurrent stroke risk, as shown in Antiplatelet Trialists Collaboration (2002, 6,898 citations), reducing long-term disability and healthcare costs. Kernan et al. (2014) guidelines improve patient outcomes by standardizing blood pressure, lipid, and lifestyle interventions post-discharge. Feigin et al. (2021, 6,865 citations) highlight global stroke burden, emphasizing prevention's role in lowering incidence from 1990-2019.
Key Research Challenges
Optimizing Antiplatelet Combinations
Balancing efficacy of dual therapy like aspirin-clopidogrel against bleeding risks remains unresolved beyond 21 days (Zhang et al., 2014). Long-term adherence and resistance complicate outcomes. Trials show variable benefits in non-cardioembolic subtypes.
Individualizing Anticoagulant Use
Selecting DOACs over warfarin for atrial fibrillation post-stroke requires precise risk stratification (Kernan et al., 2014). Cardioembolic vs. atherothrombotic distinctions drive regimen choice. Guidelines lack granular patient-specific algorithms.
Improving Lifestyle Adherence
Sustaining smoking cessation, diet, and exercise post-stroke faces high dropout rates (Feigin et al., 2021). Multicomponent interventions show modest gains. Meta-analyses identify behavioral barriers in diverse populations.
Essential Papers
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
Qinghua Zhang, Chao Wang, Maoyong Zheng et al. · 2014 · Cerebrovascular Diseases · 11.5K citations
<b><i>Background:</i></b> Antiplatelet agents are the mainstay for secondary prevention of non-cardioembolic stroke. This systematic review examined the safety and efficacy ...
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
Edward C. Jauch, Jeffrey L. Saver, Harold P. Adams et al. · 2013 · Stroke · 7.6K citations
Background and Purpose— The authors present an overview of the current evidence and management recommendations for evaluation and treatment of adults with acute ischemic stroke. The intended audien...
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
Antiplatelet Trialists Collaboration · 2002 · BMJ · 6.9K citations
Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic s...
Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
Valery L. Feigin, Benjamin Stark, Catherine O. Johnson et al. · 2021 · The Lancet Neurology · 6.9K citations
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
William J. Powers, Alejandro A. Rabinstein, Teri Ackerson et al. · 2019 · Stroke · 6.8K citations
Background and Purpose— The purpose of these guidelines is to provide an up-to-date comprehensive set of recommendations in a single document for clinicians caring for adult patients with acute art...
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
Walter N. Kernan, Bruce Ovbiagele, Henry R. Black et al. · 2014 · Stroke · 5.2K citations
The aim of this updated guideline is to provide comprehensive and timely evidence-based recommendations on the prevention of future stroke among survivors of ischemic stroke or transient ischemic a...
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage
J. Claude Hemphill, Steven M. Greenberg, Craig S. Anderson et al. · 2015 · Stroke · 3.9K citations
Purpose— The aim of this guideline is to present current and comprehensive recommendations for the diagnosis and treatment of spontaneous intracerebral hemorrhage. Methods— A formal literature sear...
Reading Guide
Foundational Papers
Start with Antiplatelet Trialists Collaboration (2002, 6,898 citations) for antiplatelet evidence base, then Zhang et al. (2014, 11,545 citations) meta-analysis on combinations, and Kernan et al. (2014, 5,153 citations) for comprehensive guidelines.
Recent Advances
Study Powers et al. (2019, 6,807 citations) guideline update and Feigin et al. (2021, 6,865 citations) for global burden informing prevention priorities.
Core Methods
Meta-analyses of RCTs for efficacy (e.g., hazard ratios); GRADE for evidence grading in guidelines; risk calculators for patient stratification.
How PapersFlow Helps You Research Secondary Prevention after Ischemic Stroke
Discover & Search
Research Agent uses searchPapers and citationGraph on 'aspirin clopidogrel secondary stroke prevention' to map 11,545-cited Zhang et al. (2014) connections, then findSimilarPapers for regimen comparisons. exaSearch uncovers adherence studies linked to Kernan et al. (2014) guidelines.
Analyze & Verify
Analysis Agent applies readPaperContent to extract hazard ratios from Zhang et al. (2014), verifies meta-analysis stats via runPythonAnalysis (pandas for forest plots), and uses verifyResponse (CoVe) with GRADE grading for evidence quality on antiplatelet efficacy.
Synthesize & Write
Synthesis Agent detects gaps in long-term dual therapy data via gap detection, flags contradictions between Jauch et al. (2013) and Powers et al. (2019); Writing Agent uses latexEditText, latexSyncCitations for guideline summaries, and latexCompile for protocol flowcharts.
Use Cases
"Run meta-regression on antiplatelet recurrence rates from stroke trials"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (NumPy/pandas meta-regression on hazard ratios from Zhang et al. 2014 and Antiplatelet Trialists 2002) → matplotlib risk plots output.
"Draft LaTeX guideline for post-stroke statin dosing"
Research Agent → citationGraph (Kernan 2014) → Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations + latexCompile → PDF with synced references.
"Find R code for stroke risk prediction models in prevention papers"
Research Agent → paperExtractUrls (Feigin 2021) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis sandbox tests model on GBD data → exportCsv predictions.
Automated Workflows
Deep Research workflow scans 50+ antiplatelet papers via searchPapers → citationGraph → structured report on recurrence risks with GRADE scores. DeepScan applies 7-step CoVe to verify Kernan et al. (2014) recommendations against Zhang et al. (2014). Theorizer generates hypotheses on personalized regimens from guideline contradictions.
Frequently Asked Questions
What defines secondary prevention after ischemic stroke?
It involves antiplatelets like aspirin-clopidogrel, statins, anticoagulants for AF, and lifestyle changes to prevent recurrence (Kernan et al., 2014).
What are key methods in secondary prevention research?
Randomized trials and meta-analyses assess dual antiplatelet efficacy; guidelines synthesize evidence for risk factor control (Zhang et al., 2014; Antiplatelet Trialists Collaboration, 2002).
What are the most cited papers?
Zhang et al. (2014, 11,545 citations) on aspirin-clopidogrel; Kernan et al. (2014, 5,153 citations) guidelines; Jauch et al. (2013, 7,614 citations).
What open problems exist?
Optimal dual therapy duration, adherence strategies, and personalization for subtypes remain unresolved (Zhang et al., 2014; Feigin et al., 2021).
Research Acute Ischemic Stroke Management with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Secondary Prevention after Ischemic Stroke with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Acute Ischemic Stroke Management Research Guide